In a patient with HER2+ advanced endometrial cancer, do you include IO(+/- olaparib) in their treatment regimen, or only trastuzumab in addition to carboplatin/paclitaxel?

This is a data-free zone and an excellent question. We don't yet know the efficacy of checkpoint inhibitor therapy in pMMR, HER2-positive, p53 mutated tumors, although the ad hoc RUBY data presented at ESMO suggest that p53 mutated tumors are responsive to immunotherapy. I eagerly await the histolog...

In a patient with HER2+ advanced endometrial cancer, my first recommendation would be enrollment on GY-026, a randomized phase II/III trial comparing chemotherapy alone to chemotherapy plus trastuzumab or chemotherapy plus trastuzumab and pertuzumab. If trial enrollment was not a feasible option, tr...

The current published literature demonstrating the benefit of Trastuzumab added to chemo is based on a phase II trial only. The added benefit of IO to chemo is based on randomized phase III trials. Due to this, for now, I favor chemo/IO combination in this subset of the patients. I currently encoura...